Infertility is a common condition with important psychological, economical, demographical and medical implications. WHO estimates that “60- 80 million couples worldwide are currently suffering from infertility.” Quilatte Haiwane Manwiya (oligospermia) is one of the most common causes of male infertility. In conventional system, various drugs are being used to increase sperm count, but these drugs are expensive and their long term use produces several adverse effects too. Therefore, keeping in the mind about the need of the hour an open, uncontrolled clinical trial was carried out on 30 infertile patients of Quilatte Haiwane Manwiya. Each patient was given trial formulation Sufoofe Muallif - 5 grams once daily for 60 days. The assessment of efficacy of treatment was carried out on the basis of objective parameters (Semen analysis for sperm count, motility, morphology and hormone profile for serum testosterone, LH, FSH). The results were analyzed statistically by using Wilcoxon matched-paired signed ranks test, one tail paired-T test and Kruskal- Wallis test. After the trial, significant improvement was found in various objective parameters; sperm count (10.53 ± 1.30 to 18.06 ± 2.57, P<0.001), sperm motility (21.70 ± 3.80 to 46.56 ± 5.06, P<0.001) and sperm morphology (76.2 ± 6.40 to 91.9 ± 4.22, P<0.01). The changes in hormone profile (serum Testosterone, LH, FSH) were not significant (P>0.05). Safety parameters were remained within normal limits after the trial. This study suggests that Sufoof Muallif has exhibited a good response in the improvement of semen markers; sperm count, sperm motility and sperm morphology. Furthermore, no adverse effect was observed and safety parameters remained within normal limits. Thus it might be concluded that the Test drug is safe and effective for the treatment of Quilatte Haiwane Manwiya (oligospermia).